HomeMarket NewsApollomics Stock Surges 76% After Positive Report on Brain Cancer Therapy

Apollomics Stock Surges 76% After Positive Report on Brain Cancer Therapy

Actionable Trade Ideas

always free

MRI Brain Scan of head and skull with hand pointing

haydenbird

Shares of Apollomics (NASDAQ:APLM) experienced a remarkable 76% surge on Friday, following a positive report on the effectiveness of its drug vebreltinib in treating glioblastoma multiforme (GBM), an aggressive form of brain cancer.

The company announced that a patient with GBM and a PTPRZ-MET fusion gene, who had previously received radiotherapy and temozolomide, exhibited an β€œimpressive partial response” after eight weeks of treatment with vebreltinib as a monotherapy.

The results were presented at the European Society of Medical Oncology Congress in Spain earlier this week by the Veneto Institute of Oncology.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.